Anticarbamylated protein antibodies as a diagnostic marker in patients with rheumatoid arthritis and it’s correlation to disease activity in Assiut governorate
Mostafa M. Abdelkareem, Mohamed I. Abdelkareem, Mohamed Z. Shoaeir, Sara A. MohamedBackground and aim
Rheumatoid arthritis (RA) is a prevalent autoimmune disorder affecting ∼1% of the global population, characterized by chronic inflammatory arthritis and potential extra-articular manifestations. We aimed to assess the levels of anti-carbamylated protein (anti-CarP) antibodies in RA patients and evaluate their utility as a diagnostic biomarker, as well as their correlation with disease activity and severity, within a population from Assiut Governorate, Egypt.
Patients and methods
This case-control study enrolled 50 RA patients, aged 28–55 years, who fulfilling the 2010 ACR/EULAR classification criteria, and 50 age- and sex-matched healthy controls. All participants underwent a comprehensive clinical evaluation. Laboratory investigations included measurement of rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and anti-CarP antibodies.
Results
The sensitivity for diagnosing RA was highest for RF (70%), compared with anti-CCP (52%) and anti-CarP (56%;
Conclusion
Anti-CarP antibodies exhibit high specificity and a significant association with disease severity in RA patients, supporting their potential role as a complementary serological marker for prognosis and disease monitoring.